Durable Cancer Therapeutics

Durable Therapeutics is a preclinical-stage biotechnology company dedicated to overcoming cancer drug resistance and recurrence by targeting 'persister' cells. These cells represent a subpopulation of cancer cells that survive initial therapy and eventually lead to relapse. Leveraging research from the University of Texas MD Anderson Cancer Center, the company identifies specific metabolic and epigenetic vulnerabilities unique to these surviving cells. Their mission is to develop small molecule therapies that, when combined with standard treatments, eliminate minimal residual disease and provide long-lasting clinical outcomes for patients. The company's proprietary platform enables the discovery of targets that are essential for the survival of cancer cells in a dormant or slow-growing state. By eradicating these cells, Durable Therapeutics aims to transform cancer from a manageable condition into a curable one.